VYNE Therapeutics Inc. (VYNE): Price and Financial Metrics

VYNE Therapeutics Inc. (VYNE): $6.53

-0.07 (-1.06%)

POWR Rating

Component Grades








Add VYNE to Watchlist
Sign Up

Industry: Biotech




#90 of 378

in industry

VYNE Price/Volume Stats

Current price $6.53 52-week high $9.90
Prev. close $6.60 52-week low $1.99
Day low $6.31 Volume 17,398
Day high $6.70 Avg. volume 488,526
50-day MA $4.84 Dividend yield N/A
200-day MA $4.35 Market Cap 21.36M

VYNE Stock Price Chart Interactive Chart >

VYNE Stock Summary

  • The ratio of debt to operating expenses for VYNE THERAPEUTICS INC is higher than it is for about merely 0.41% of US stocks.
  • With a year-over-year growth in debt of -100%, VYNE THERAPEUTICS INC's debt growth rate surpasses just 0.02% of about US stocks.
  • The volatility of VYNE THERAPEUTICS INC's share price is greater than that of 99.2% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to VYNE, based on their financial statements, market capitalization, and price volatility, are API, ZLAB, MIRM, LGVN, and PGEN.
  • VYNE's SEC filings can be seen here. And to visit VYNE THERAPEUTICS INC's official web site, go to www.menlotherapeutics.com.

VYNE Valuation Summary

  • In comparison to the median Healthcare stock, VYNE's price/earnings ratio is 102.9% lower, now standing at -0.7.
  • Over the past 65 months, VYNE's EV/EBIT ratio has gone up 42.8.

Below are key valuation metrics over time for VYNE.

Stock Date P/S P/B P/E EV/EBIT
VYNE 2023-05-23 60.6 0.9 -0.7 0.2
VYNE 2023-05-22 57.8 0.9 -0.7 0.2
VYNE 2023-05-19 56.8 0.9 -0.7 0.2
VYNE 2023-05-18 55.8 0.8 -0.7 0.2
VYNE 2023-05-17 59.0 0.9 -0.7 0.2
VYNE 2023-05-16 58.0 0.9 -0.7 0.2

VYNE Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -251.36%.
  • Its year over year cash and equivalents growth rate is now at -57.19%.
  • The 2 year revenue growth rate now stands at 517.94%.
VYNE's revenue has moved down $10,675,000 over the prior 27 months.

The table below shows VYNE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 2.763 -35.343 -24.835
2022-06-30 6.682 -45.759 -36.661
2022-03-31 10.814 -53.791 -48.109
2021-12-31 14.755 -56.367 -73.329
2021-09-30 16.749 -71.724 -84.94
2021-06-30 15.932 -77.82 -88.369

VYNE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VYNE has a Quality Grade of D, ranking ahead of 14.91% of graded US stocks.
  • VYNE's asset turnover comes in at 0.132 -- ranking 235th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows VYNE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.132 0.856 -2.324
2021-03-31 0.194 0.926 -5.086
2020-12-31 0.170 0.934 -4.672
2020-09-30 0.140 0.949 -4.901
2020-06-30 0.115 0.964 -4.606
2020-03-31 0.016 0.845 -1.853

VYNE Price Target

For more insight on analysts targets of VYNE, see our VYNE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.00 Average Broker Recommendation 1.58 (Moderate Buy)

VYNE Therapeutics Inc. (VYNE) Company Bio

VYNE Therapeutics Inc. operates as a clinical stage bio-pharmaceutical company. The Company develops medicines and therapies for the treatment of chronic pruritus and cough. VYNE Therapeutics serves customers worldwide.

VYNE Latest News Stream

Event/Time News Detail
Loading, please wait...

VYNE Latest Social Stream

Loading social stream, please wait...

View Full VYNE Social Stream

Latest VYNE News From Around the Web

Below are the latest news stories about VYNE THERAPEUTICS INC that investors may wish to consider to help them evaluate VYNE as an investment opportunity.

VYNE Therapeutics to Attend BIO International Convention

BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that members of management will attend the Biotechnology Innovation Organization (BIO) International Convention, taking place June 5-8, 2023 at the Boston Convention & Exhibition Center in Boston,

Yahoo | May 18, 2023

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in anticipation of an IND filing by year-end 2023 BRIDGEWATER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focu

Yahoo | May 11, 2023

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has demonstrated a potent anti-inflammatory and anti-fibrotic effect in multiple validated preclinical models of autoimmune disease IND-enabling studies are ongoing in anticipation of an IND filing by year-end BRIDGEWATER, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company devel

Yahoo | May 1, 2023

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

VYN201 at the 0.5 mg/ml and 1 mg/ml doses demonstrated statistically significant reductions in lung fibrosis and hydroxyproline levels compared to placeboReduction in lung fibrosis from VYN201 treatment resulted in significant improvements in blood oxygen saturation and functional lung volumeData further supports potential broad utility of VYN201 as a potent locally-administered anti-inflammatory and anti-fibrotic molecule BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics I

Yahoo | April 19, 2023

7 Sorry Pharma Stocks to Sell in April Before It’s Too Late

You have to be patient when investing in pharma stocks.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | April 16, 2023

Read More 'VYNE' Stories Here

VYNE Price Returns

1-mo 24.14%
3-mo 119.13%
6-mo 60.59%
1-year N/A
3-year -96.21%
5-year N/A
YTD 141.85%
2022 -85.29%
2021 -83.86%
2020 -65.95%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!